Evidence map›Paper›PMID 34804433›Full record

ArticleIranian journal of basic medical sciences2021

Dystrophin gene editing by CRISPR/Cas9 system in human skeletal muscle cell line (HSkMC).

Mahintaj Dara, Vahid Razban, Mohsen Mazloomrezaei, Maryam Ranjbar, Marjan Nourigorji, Mehdi Dianatpour

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of basic medical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mahintaj DaraDepartment of Molecular Medicine, School of Advanced Medical Science and Technology, Shiraz University of Medical Science, Shiraz, Iran.
Vahid RazbanDepartment of Molecular Medicine, School of Advanced Medical Science and Technology, Shiraz University of Medical Science, Shiraz, Iran.
Mohsen MazloomrezaeiStudent Research Committee, Shiraz University of Medical Science, Shiraz, Iran.
Maryam RanjbarDepartment of Medical Genetics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Marjan NourigorjiDepartment of Medical Genetics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Mehdi DianatpourDepartment of Medical Genetics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Shiraz University · IRShiraz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesDuchene muscular dystrophy (DMD) is a progressive neuromuscular disease caused by mutations in the MATERIALS AND

methodsIn this study for the exon-skipping approach, we designed a new pair of guide RNAs (gRNA) to induce large deletion of exons 48 to 53 in the

resultsData showed successful editing of

conclusionThis study demonstrated that the removal of exons 48-53 by the CRISPR / Cas9 system did not alter the expression of the

Indexed as

CRISPR/Cas9DMDDystrophinGene editingHSkMC

Identifiers

PMID34804433
PMCPMC8591754
OpenAlexW3191644042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.